| ²é¿´: 2418 | »Ø¸´: 2 | ||
cjz1645½ð³æ (СÓÐÃûÆø)
|
[ÇóÖú]
ÇóÖúÀ¼Ë÷Àßò ×îСÓÐЧ¼ÁÁ¿ºÍ×î´óÈÕÓüÁÁ¿
|
| À¼Ë÷Àßò ×îСÓÐЧ¼ÁÁ¿ºÍ×î´óÈÕÓüÁÁ¿ÊǶàÉÙ?È»ºó,ÇëÎÊÕâ¸öÒ»°ãÈ¥ÄÄÀïÕÒµÄ. |
» ²ÂÄãϲ»¶
ÊÛSCIÒ»ÇøÎÄÕ£¬ÎÒ:8 O5 51O 54,¿ÆÄ¿ÆëÈ«,¿É+¼±
ÒѾÓÐ4È˻ظ´
ÊÛSCIÒ»ÇøÎÄÕ£¬ÎÒ:8 O5 51O 54,¿ÆÄ¿ÆëÈ«,¿É+¼±
ÒѾÓÐ6È˻ظ´
ÊÛSCIÒ»ÇøÎÄÕ£¬ÎÒ:8 O5 51O 54,¿ÆÄ¿ÆëÈ«,¿É+¼±
ÒѾÓÐ4È˻ظ´
ÊÛSCIÒ»ÇøÎÄÕ£¬ÎÒ:8 O5 51O 54,¿ÆÄ¿ÆëÈ«,¿É+¼±
ÒѾÓÐ5È˻ظ´
ÊÛSCIÒ»ÇøÎÄÕ£¬ÎÒ:8 O5 51O 54,¿ÆÄ¿ÆëÈ«,¿É+¼±
ÒѾÓÐ5È˻ظ´
ÊÛSCIÒ»ÇøÎÄÕ£¬ÎÒ:8 O5 51O 54,¿ÆÄ¿ÆëÈ«,¿É+¼±
ÒѾÓÐ8È˻ظ´
ÊÛSCIÒ»ÇøÎÄÕ£¬ÎÒ:8 O5 51O 54,¿ÆÄ¿ÆëÈ«,¿É+¼±
ÒѾÓÐ8È˻ظ´
ÊÛSCIÒ»ÇøÎÄÕ£¬ÎÒ:8 O5 51O 54,¿ÆÄ¿ÆëÈ«,¿É+¼±
ÒѾÓÐ10È˻ظ´
ÊÛSCIÒ»ÇøÎÄÕ£¬ÎÒ:8 O5 51O 54,¿ÆÄ¿ÆëÈ«,¿É+¼±
ÒѾÓÐ6È˻ظ´
ÊÛSCIÒ»ÇøÎÄÕ£¬ÎÒ:8 O5 51O 54,¿ÆÄ¿ÆëÈ«,¿É+¼±
ÒѾÓÐ6È˻ظ´
» ±¾Ö÷ÌâÏà¹Ø¼ÛÖµÌùÍÆ¼ö£¬¶ÔÄúͬÑùÓаïÖú:
¿¼ÑÐÌâÄ¿ÇóÖú£¬ÔÚÏßµÈ
ÒѾÓÐ5È˻ظ´
ÇóÖú£º¶¯ÎïLD50Èç¹ûÖªµÀÁË£¬ÔõÃ´ÍÆÖª¶¯ÎïµÄҩЧµÄÓÐЧµÍÖиßÈý¸ö¼ÁÁ¿°¡£¿
ÒѾÓÐ17È˻ظ´
¡¾ÇóÖú¡¿ÎªÊ²Ã´MTTÊÔÑéÖ»³öÏÖÒ»´Î¼ÁÁ¿ÒÀÀµÐÔ½á¹û£¿Çë½Ì
ÒѾÓÐ4È˻ظ´
¡¾ÇóÖú¡¿´óÊó¹àθ¼ÁÁ¿
ÒѾÓÐ4È˻ظ´
¡¾ÇóÖú¡¿¹ØÓÚ´óÊó¹àθ¼ÁÁ¿
ÒѾÓÐ11È˻ظ´
¡¾ÇóÖú¡¿Èç¹û²»·Ö¸ßµÍ¼ÁÁ¿×飬´óÊóʵÑéÓÃÁ¿ÊÇÈËÁÙ´²ÓÃÁ¿°´ÌåÖØ»»ËãËùµÃ¼ÁÁ¿µÄ¶àÉÙ±¶£¿
ÒѾÓÐ6È˻ظ´
¡¾ÇóÖú¡¿ÎªÊ²Ã´Ò©ÀíʵÑéÖбØÐëÓмÁÁ¿µÄÒÀÀµÐÔ¼´dose-response¹ØÏµ
ÒѾÓÐ6È˻ظ´
¡¾ÇóÖú¡¿ÈçºÎ³ÆÈ¡Ð¡¼ÁÁ¿µÄ´ß»¯¼Á¹ÌÌ壨ҪÇóÎÞË®ÎÞÑõ£©
ÒѾÓÐ7È˻ظ´
¡¾ÇóÖú¡¿ÊµÑ鶯Îï¼ÁÁ¿µÄÑ¡Ôñ
ÒѾÓÐ16È˻ظ´
¡¾ÇóÖú¡¿À¼Ë÷Àßò³¦ÈÜÆ¬Èܳö¶ÈÎÊÌâ
ÒѾÓÐ9È˻ظ´
liffy
гæ (СÓÐÃûÆø)
- Ó¦Öú: 0 (Ó×¶ùÔ°)
- ½ð±Ò: 1652.7
- ºì»¨: 1
- Ìû×Ó: 77
- ÔÚÏß: 10.3Сʱ
- ³æºÅ: 1065837
- ×¢²á: 2010-07-28
- ÐÔ±ð: GG
- רҵ: ÁÙ´²Ò©Àí

2Â¥2011-05-12 17:46:16
konglongli
ľ³æ (СÓÐÃûÆø)
- Ó¦Öú: 0 (Ó×¶ùÔ°)
- ½ð±Ò: 3135.4
- ºì»¨: 1
- Ìû×Ó: 191
- ÔÚÏß: 192.2Сʱ
- ³æºÅ: 104251
- ×¢²á: 2005-11-15
¡¾´ð°¸¡¿Ó¦Öú»ØÌû
cjz1645(½ð±Ò+2): 2011-05-15 20:31:02
|
For optimal effect lansoprazole should be taken once daily in the morning. Lansoprazole should be taken at least 30 minutes before food (see section 5.2). Capsules should be swallowed whole with liquid. Treatment of duodenal ulcer: The recommended dose is 30mg once daily for 2 weeks. In patients not fully healed within this time, the medication is continued at the same dose for another two weeks. Treatment of gastric ulcer: The recommended dose is 30mg once daily for 4 weeks. The ulcer usually heals within 4 weeks, but in patients not fully healed within this time, the medication may be continued at the same dose for another 4 weeks. Reflux oesophagitis: The recommended dose is 30mg once daily for 4 weeks. In patients not fully healed within this time, the treatment may be continued at the same dose for another 4 weeks. Prophylaxis of reflux oesophagitis: 15mg once daily. The dose may be increased up to 30mg daily as necessary. Treatment of NSAID associated benign gastric and duodenal ulcers in patients requiring continued NSAID treatment: 30mg once daily for four weeks. In patients not fully healed the treatment may be continued for another four weeks. For patients at risk or with ulcers that are difficult to heal, a longer course of treatment and/or a higher dose should probably be used. Prophylaxis of NSAID associated gastric and duodenal ulcers in patients at risk (such as age 65 or history of gastric or duodenal ulcer) requiring prolonged NSAID treatment: 15mg once daily. If the treatment fails the dose 30mg once daily should be used. Symptomatic gastro-oesophageal reflux disease: The recommended dose is 15mg or 30mg daily. Relief of symptoms is obtained rapidly. Individual adjustment of dosage should be considered. If the symptoms are not relieved within 4 weeks with a daily dose of 30mg, further examinations are recommended. Zollinger-Ellison syndrome: The recommended initial dose is 60mg once daily. The dose should be individually adjusted and the treatment should be continued for as long as necessary. Daily doses of up to 180mg have been used. If the required daily dose exceeds 120mg, it should be given in two divided doses. Impaired hepatic or renal function: There is no need for a dose adjustment in patients with impaired renal function. Patients with moderate or severe liver disease should be kept under regular supervision and a 50% reduction of the daily dose is recommended (see section 4.4 and 5.2). Elderly: Due to reduced clearance of lansoprazole in the elderly an adjustment of dose may be necessary based on individual requirements. A daily dose of 30mg should not be exceeded in the elderly unless there are compelling clinical indications. Children: The use of lansoprazole is not recommended in children as clinical data are limited (see also section 5.2). Treatment of small children below one year of age should be avoided as available data have not shown beneficial effects in the treatment of gastro-oesophageal reflux disease. Daily doses of up to 180mg of lansoprazole orally and up to 90mg of lansoprazole intravenously have been administered in trials without significant undesirable effects |
3Â¥2011-05-13 15:25:47













»Ø¸´´ËÂ¥